# GDRX — GoodRx Holdings · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** GDRX  
**Sources:** 14  
**Published:** 2026-10-27  
**Canonical:** https://app.k3vl4r.com/research/deep-research-gdrx-goodrx-holdings-catalysts-narrative-risks-9635

---

# GoodRx Holdings (GDRX) — Research Brief as of 2026-10-27

## Recent Catalysts (last ~1–3 months)

**Q2 2026 earnings (early August 2026).** GoodRx reported Q2 2026 results in early August (Aug 5 per [[4]](https://www.marketbeat.com/stocks/NASDAQ/GDRX/earnings/), Aug 6 per [[8]](https://www.barchart.com/stocks/quotes/GDRX/news)). Top-line results beat consensus: revenue of $200.41M (down 1.3% YoY but above the ~$193.23M consensus estimate) and EPS of $0.08, meeting estimates [[4]](https://www.marketbeat.com/stocks/NASDAQ/GDRX/earnings/). Segment growth was strong — Pharma Direct revenue up 76% YoY and subscriptions up 39% YoY — prompting the company to raise full-year revenue and EBITDA guidance [[8]](https://www.barchart.com/stocks/quotes/GDRX/news).

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-gdrx-goodrx-holdings-catalysts-narrative-risks-9635 (free to sign up)._
